merger
PharmaGap is pursuing a strategy to partner its
lead drug candidates at the pre-clinical or early clinical trial stage. The
Company recognizes that its strengths rest in drug design and “proof
of principle” validation and
that larger pharmaceutical/biotech partners have the resources necessary
to move the Company’s compounds into human clinical use.